Publications
79
Citations
630
Est. group size
~10
Recurring co-author estimate
Active years
38
Publishing since 1989
Andrew Johns is a clinical cancer researcher focused on genitourinary cancers, including kidney (renal cell carcinoma), testicular germ cell tumors, and penile cancer. His work centers on evaluating immunotherapy combinations and other drug treatments in clinical trials, as well as identifying biological markers that could help predict how patients respond to treatment. Prospective students would likely engage with multi-institutional clinical trial data, patient outcome analyses, and translational research connecting tumor biology to treatment strategies.
Publication output has grown substantially over the last decade, rising from just a few papers per year in 2017-2018 to a peak of 17 in 2025, indicating an increasingly active research program.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- A multi-institution analysis of outcomes with first-line ipilimumab and nivolumab for 514 patients with metastatic clear cell renal cell carcinoma by number of doses.
Journal of Clinical Oncology · 2026
- Clinical outcomes and tolerability of ipilimumab/nivolumab in older (≥70 years) versus younger patients with metastatic clear cell RCC: A multi-institutional analysis of 514 patients.
Journal of Clinical Oncology · 2026
- Divergent biology and outcomes of somatic transformations (SM) in germ cell tumors (GCT).
Journal of Clinical Oncology · 2026
- A phase II trial of nivolumab, ipilimumab and cabozantinib in patients with brain metastases from renal cell carcinoma.
Journal of Clinical Oncology · 2026
- Front-line chemo-immunotherapy for advanced penile cancer: ready for prime time?
British Journal of Cancer · 2026
- Divergent biology and outcomes of somatic transformations in germ cell tumors
The Oncologist · 2026
- SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade
Nature · 2025
- High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors
Clinical Cancer Research · 2025
- Bilateral Germ Cell Tumor of the Testis: Biological and Clinical Implications for a Stem Versus Genetic Origin of Cancers
Cells · 2025
- Spatial analysis of the immune microenvironment and identification of phenotypes of prognostic significance in penile squamous cell carcinoma (PSCC).
Journal of Clinical Oncology · 2025
- The influence of body composition on the survival of patients with metastatic clear cell renal carcinoma (mccRCC) treated with nivolumab (nivo) + ipilimumab (ipi).
Journal of Clinical Oncology · 2025
- Expression of tissue factor (TF) in penile squamous cell carcinoma (PSCC) and enrichment in HPV-negative cases.
Journal of Clinical Oncology · 2025
- IP27-36 TISSUE FACTOR EXPRESSION IN PENILE SQUAMOUS CELL CARCINOMA: A NOVEL THERAPEUTIC TARGET
The Journal of Urology · 2025
- Bilateral germ cell tumor of the testis (TGCT): Implications for a stem cell versus genetic origin of cancers.
Journal of Clinical Oncology · 2025
- Tissue Factor Expression in Penile Squamous Cell Carcinoma: A Marker of HPV-Independent Disease
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Journal of Clinical Oncology×23
- Cancer Immunology Immunotherapy×5
- The Oncologist×4
- Journal of Thoracic Oncology×4
- Clinical Lung Cancer×2
- Abdul Miah
Medicine · The Ohio State University
- Yuanquan Yang
Medicine · The Ohio State University
- Lingbin Meng
Medicine · The Ohio State University
- Adam Khorasanchi
Medicine · The Ohio State University
- Merve Hasanov
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile